Dr. Zerrouk Presents at CERN

Zecotek Presents at CERN’s Colloquium on Silicon Photomultipliers

Singapore, March 16, 2011 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it recently participated in Colloquium on Silicon Photomultipliers, an industry/academia matching event hosted by CERN’s Technology Transfer Network for Particle, Astroparticle and Nuclear Physics. The main objective of the event was to provide an overview on state-of-the-art photo detection technologies and to define a roadmap towards collaborative research and development on key solutions in silicon based photo detection. The event brought together experts from academia and industry active in the field of photon detection, including over 130 scientists and industry representatives from CERN’s twenty member states, plus representatives from Brazil, Canada and Japan.

“It was an honour to present how Zecotek has advanced the basis of silicon photomultipliers to such a prestigious audience,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “CERN is one of the world’s leading centres for scientific research, and they have recognized the importance of new technologies including our own proprietary MAPD solid-state photo detectors and Integrated Display Modules. We continue to work with CERN on a number of important experiments and look forward to expanding our role in support of this monumental scientific quest.”

Zecotek was represented by Dr. A.F. Zerrouk who was among the keynote industry presenters. Dr. Zerrouk’s presentation focused on Zecotek’s proprietary MAPD solid-state photo detector and IDM (Integrated Display Module) and was supported by the results of testing of Zecotek MAPD’s by leading researchers and institutions. The response from the presentation has been very positive and has attracted significant interest in Zecotek’s MAPD, from a number of leading institutions, in particular in the area of High Energy Physics and Medical Imaging.

Zecotek has established a close working relationship with the Compact Muon Solenoid (CMS) experiment at CERN, Switzerland, which is using Zecotek’s proprietary MAPD-3N Micro-pixel Avalanche Photo Diodes. Not only does Zecotek’s MAPD-3Ns feature important radiation hardness, its unique, large micro-pixel density of 15,000 per mm2 provides the high linearity required in a hadronic detector such as the CMS Hadron Calorimeter. CERN is working with several of Zecotek’s photo detector configurations including single MAPDs and standard and customized arrays.

About CERN
CERN, the European Organization for Nuclear Research, is one of the world’s largest and most respected centres for scientific research. Its business is fundamental physics, finding out what the Universe is made of and how it works. At CERN, the world’s largest and most complex scientific instruments are used to study the basic constituents of matter — the fundamental particles. By studying what happens when these particles collide, physicists learn about the laws of Nature. CERN is the home of the Large Hadron Collider (LHC). LHC experiments will address questions such as what gives matter its mass, what the invisible 96% of the Universe is made of, why nature prefers matter to antimatter and how matter evolved from the first instants of the Universe’s existence. The instruments used at CERN are particle accelerators and detectors. Accelerators boost beams of particles to high energies before they are made to collide with each other or with stationary targets. Detectors observe and record the results of these collisions. Founded in 1954, the CERN Laboratory sits astride the Franco–Swiss border near Geneva. It was one of Europe’s first joint ventures and now has 20 Member States. For more information about CMS please visit http://cms.web.cern.ch/cms/Detector/WhatCMS/index.html.

– 30 –

About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industries. Founded in 2003, the company operates three distinct divisions: imaging, lasers and 3D display, with labs located in Canada, USA, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Zecotek Photonics Inc.
Michael Minder
T: (604) 827-5212
[email protected]
CHF Investor Relations
Julia Clark, Account Manager
T: (416) 868-1079 x236
[email protected]

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.